Pages that link to "Q72486191"
Jump to navigation
Jump to search
The following pages link to Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal (Q72486191):
Displaying 50 items.
- Inhibition of monoamine oxidase B in the brains of smokers (Q24322939) (← links)
- A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys (Q24537332) (← links)
- MAO-inhibitors in Parkinson's Disease (Q24629770) (← links)
- A Review of Sleep and Its Disorders in Patients with Parkinson's Disease in Relation to Various Brain Structures (Q26744733) (← links)
- A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease (Q27311651) (← links)
- Molecular imaging of movement disorders (Q28071336) (← links)
- Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease (Q28215872) (← links)
- Rasagiline: a review of its use in the management of Parkinson's disease (Q28239730) (← links)
- Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells (Q28298685) (← links)
- Rasagiline [N-propargyl-1R( )-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B (Q28346410) (← links)
- Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal (Q28372146) (← links)
- Monoamine oxidase and catechol-O-methyltransferase inhibitors (Q33545299) (← links)
- Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. (Q33708210) (← links)
- Monoamine oxidase and cigarette smoking. (Q33845951) (← links)
- Functional brain imaging of tobacco use and dependence (Q33875395) (← links)
- In vivo brain imaging of human exposure to nicotine and tobacco (Q33946922) (← links)
- CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease (Q33994583) (← links)
- Parkinson's disease: medical and surgical treatment (Q34353538) (← links)
- Slow onset of CNS drugs: can changes in protein concentration account for the delay? (Q34360401) (← links)
- Is the onset of psychoactive drug effects compatible with a protein-synthesis mechanism? (Q35162940) (← links)
- Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease (Q35454622) (← links)
- A review of graphical methods for tracer studies and strategies to reduce bias (Q35617870) (← links)
- Evaluation of the Inhibitory Effects of Bavachinin and Bavachin on Human Monoamine Oxidases A and B. (Q36237385) (← links)
- Translational neuroimaging: positron emission tomography studies of monoamine oxidase. (Q36304383) (← links)
- Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease (Q36468704) (← links)
- Current status of symptomatic medical therapy in Parkinson's disease (Q37131229) (← links)
- Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline (Q37614697) (← links)
- Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? (Q37724555) (← links)
- Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain (Q37731710) (← links)
- Kinetic behavior and reversible inhibition of monoamine oxidases—enzymes that many want dead (Q37942337) (← links)
- Rasagiline in Parkinson's Disease (Q37942342) (← links)
- Rasagiline in treatment of Parkinson's disease. (Q39315311) (← links)
- Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs (Q39438767) (← links)
- Pharmacokinetic optimisation in the treatment of Parkinson's disease (Q40937861) (← links)
- In Vivo Metabolic Trapping Radiotracers for Imaging Monoamine Oxidase-A and -B Enzymatic Activity. (Q42110236) (← links)
- Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects? (Q42212067) (← links)
- Biphasic effects of selegiline on striatal dopamine: lack of effect on methamphetamine-induced dopamine depletion (Q43611877) (← links)
- Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease (Q44011623) (← links)
- A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation (Q44290887) (← links)
- Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. (Q46171586) (← links)
- Inhibition of monoamine oxidase by selected C6-substituted chromone derivatives (Q46385237) (← links)
- Flavonoids from Sideritis Species: Human Monoamine Oxidase (hMAO) Inhibitory Activities, Molecular Docking Studies and Crystal Structure of Xanthomicrol. (Q46737135) (← links)
- Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders (Q47593688) (← links)
- An acute dose of nicotine does not inhibit MAO B in baboon brain in vivo (Q48424971) (← links)
- Species differences in [11C]clorgyline binding in brain (Q48770776) (← links)
- Synthesis and in vivo studies of a specific monoamine oxidase B inhibitor: 5-[4-(benzyloxy)phenyl]-3-(2-cyanoethyl)- 1,3,4-oxadiazol-[11C]-2(3H)-one (Q49125848) (← links)
- MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([(18)F]-AV-1451) Binding. (Q50061690) (← links)
- [Pharmacological treatment of motor symptoms in Parkinson's diseases]. (Q52703430) (← links)
- 90 years of monoamine oxidase: some progress and some confusion. (Q53413619) (← links)
- Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease (Q64072741) (← links)